In a turn of events that is sure to be closely watched, the U.S. Supreme Court is poised to dive into a crucial debate concerning the status of abortion access nationwide. The Court will assess the legality and access to Mifepristone, a primary drug used in medical abortions. This decision comes as an appeal from the Biden Administration and the manufacturer of the drug in response to a lower court ruling that threatens to limit the drug's distribution.
The implications of this are widespread, given that Mifepristone is utilized in over half the abortions not just in a specific region, but across the entire United States. However, what looms largest is the potential for additional restrictions to be placed on Mifepristone access. Should the Supreme Court concur with the lower court ruling, it would necessitate three physical doctor visits before Mifepristone can be offered to a woman, effectively eliminating the current telehealth option.
